Enhanced safety surveillance of the adjuvanted respiratory syncytial virus vaccine among Italian older adults
An adjuvanted vaccine to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in older adults has recently become available. Post-authorization safety studies (PASSs) conducted under real-world conditions complement data obtained from clinical trials characterized by s...
Saved in:
| Main Authors: | Alexander Domnich, Andrea Orsi, Piero Luigi Lai, Elvira Massaro, Carlo-Simone Trombetta, Julieta Pastorino, Charlott Roihl, Sara Tardito, Marianna Pianta, Giancarlo Icardi, Donatella Panatto |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136225000415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01) -
Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains
by: Liran Levy, et al.
Published: (2025-04-01) -
Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023–December 2024
by: Junchao Li, et al.
Published: (2025-08-01) -
Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity
by: Anna Condemi, et al.
Published: (2025-07-01) -
Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia
by: Thamir A. Alandijany, et al.
Published: (2025-08-01)